Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company focused on diseases affecting the central nervous system (CNS). Based in Boston, SAGE has a portfolio of drug candidates that modulate the gamma-aminobutyric acid (GABA) system. SAGE-547 is in development for and postpartum depression. Orally dosed SAGE-217 is in development for postpartum depression, major depressive disorder, essential tremor and Parkinson's disease.[copied from BoAML (ML)]
ML currently has a BUY on SAGE with a 12 month $200. price objective. Morgan Stanley has a $228. price target.
sagerx.com |
